Foley Hoag Represents Alcyone Therapeutics in Closing $23M in Funding

Foley Hoag LLP advised Alcyone Therapeutics, a Lowell, Massachusetts-based biotechnology company pioneering next-generation precision central nervous system (CNS) therapies, in closing $23 million in funding from funds affiliated with RTW Investments, LP.

Alcyone's precision CNS delivery technology platform allows for unprecedented control and versatility for biodistribution of genetic medicines to CNS regions of interest, including deep brain regions and spare off-target areas. Alcyone's CNS precision delivery can improve the efficiency of CNS gene therapy significantly impacting safety and efficacy, and the number of vectors needed, for an effective gene therapy.

Foley Hoag attorneys Patrick Connolly, Jeffrey Quillen, Jennifer Audeh, Brendan Burke, Sarah Ropiak and Kimberly Cyrus represented Alcyone in the transaction.